Jennifer H. Barnett

Jennifer H. Barnett

Auto-generated profile, based on publicly available information

Jennifer H. Barnett

Cambridge Cognition, University of Cambridge, Cambridge CB25 9TU, UK

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2006 in Psychological Medicine
Verified
Journal Article
Closed access
PDF file
JBJ. H. Barnett
J. H. Barnett
CSC. H. Salmond
C. H. Salmond
PJPeter Martin Jones
Peter Martin Jones
BSB. J. Sahakian
B. J. Sahakian
Background. The idea that superior cognitive function acts as a protective factor against dementia and the consequences of head injury is well established. Here we suggest the hypothesis that cognitive reserve is also important in neuropsychiatric disorders including schizophrenia, bipolar disorder and depression.Method. We review the history of passive and active models of reserve, and apply the concept to neuropsychiatric disorders. Schizophrenia is used as an exemplar because the effects of premorbid IQ and cognitive function in this disorder have been extensively studied.Results. Cognitive reserve may impact on neuropsychiatric disorders in three ways: by affecting the risk for developing the disorder, in the expression of symptoms within disorders, and in patients' functional outcome. Cognitive failure below a certain threshold may alone, or in combination with common psychiatric symptoms, produce neuropsychiatric syndromes.Conclusions. Consideration of cognitive reserve may considerably improve our understanding of individual differences in the causes and consequences of neuropsychiatric disorders. For these reasons, the concept of cognitive reserve should be incorporated in future studies of neuropsychiatric disorder. It may be possible to enhance cognitive reserve through pharmacological or non-pharmacological means, such as education, neurocognitive activation or other treatment programmes.

27 February 2007 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
JBJ H Barnett
J H Barnett
PJPeter Martin Jones
Peter Martin Jones
TRT W Robbins
T W Robbins
UMU Müller
U Müller
The catechol-O-methyltransferase (COMT) Val158Met polymorphism is hypothesized to affect executive function in patient and control populations. Studies inconsistently report better performance on the Wisconsin Card Sort Test (WCST) in individuals with one or more Met alleles. We conducted a meta-analysis of studies published until August 2006 that reported WCST perseverative errors from healthy volunteers or patients with schizophrenia-spectrum disorders. Twelve studies met inclusion criteria (total n=1910) providing 10 samples each of patients and controls. In healthy controls, individuals with the Met/Met genotype performed better than those with the Val/Val genotype (d=0.29; 95% confidence interval (CI) 0.02–0.55; P=0.03), but this was not supported in the patient sample (d=−0.07; 95% CI −0.40 to 0.26; P=0.68). Post hoc analyses suggested that Val and Met alleles are codominant in their effects on cognition. Effect size was greater in studies published at an earlier date and may also be larger in non-Caucasian samples. Gender did not affect the results. There was no evidence of publication bias. We conclude that there is small but significant relationship between Val158Met genotype and executive function in healthy individuals but not in schizophrenia.

7 May 2014 in BMC Neurology
Verified
Journal Article
Open access
PDF file
JBJennifer H Barnett
Jennifer H Barnett
LLLily Lewis
Lily Lewis
ABAndrew D Blackwell
Andrew D Blackwell
Matthew TaylorMatthew Taylor
Matthew Taylor
Intervention and treatment in Alzheimer’s disease dementia (AD-dementia) can be cost effective but the majority of patients are not diagnosed in a timely manner. Technology is now available that can enable the earlier detection of cognitive loss associated with incipient dementia, offering the potential for earlier intervention in the UK health care system. This study aimed to determine to what extent the timing of an intervention affects its cost-effectiveness.

1 June 2007 in The British Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
JBJennifer H. Barnett
Jennifer H. Barnett
UWUrsula Werners
Ursula Werners
SSSandra M. Secher
Sandra M. Secher
KHKatherine E. Hill
Katherine E. Hill
RBRossa Brazil
Rossa Brazil
PJPeter Martin Jones
Peter Martin Jones
Background: Substance use is implicated in the cause and course of psychosis.Aims: To characterise substance and alcohol use in an epidemiologically representative treatment sample of people experiencing a first psychotic episode in south Cambridgeshire.Method: Current and lifetime substance use was recorded for 123 consecutive referrals to a specialist early intervention service. Substance use was compared with general population prevalence estimates from the British Crime Survey.Results: Substance use among people with first-episode psychosis was twice that of the general population and was more common in men than women. Cannabis abuse was reported in 51% of patients (n=62) and alcohol abuse in 43% (n=53). More than half (n=68, 55%) had used Class A drugs, and 38% (n=43) reported polysubstance abuse. Age at first use of cannabis, cocaine, ecstasy and amphetamine was significantly associated with age at first psychotic symptom.Conclusions: Substance misuse is present in the majority of people with first-episode psychosis and has major implications for management. The association between age at first substance use and first psychotic symptoms has public health implications.

1 July 2010 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
JBJennifer H. Barnett
Jennifer H. Barnett
TRTrevor W. Robbins
Trevor W. Robbins
VLVerity C. Leeson
Verity C. Leeson
BSBarbara J. Sahakian
Barbara J. Sahakian
EJEileen M. Joyce
Eileen M. Joyce
ABAndrew D. Blackwell
Andrew D. Blackwell

1 January 2017 in Psychiatry Research
Verified
Journal Article
Open access
AHAnja P. Husa
Anja P. Husa
JMJani Moilanen
Jani Moilanen
GMGraham K. Murray
Graham K. Murray
RMRiikka Marttila
Riikka Marttila
MHMarianne Haapea
Marianne Haapea
EJErika Jääskeläinen
Erika Jääskeläinen
This naturalistic study analysed the association between cumulative lifetime antipsychotic dose and cognition in schizophrenia after an average of 16.5 years of illness. Sixty participants with schizophrenia and 191 controls from the Northern Finland Birth Cohort 1966 were assessed at age 43 years with a neurocognitive test battery. Cumulative lifetime antipsychotic dose-years were collected from medical records and interviews. The association between antipsychotic dose-years and a cognitive composite score based on principal component analysis was analysed using linear regression. Higher lifetime antipsychotic dose-years were significantly associated with poorer cognitive composite score, when adjusted for gender, onset age and lifetime hospital treatment days. The effects of typical and atypical antipsychotics did not differ. This is the first report of an association between cumulative lifetime antipsychotic dose and global cognition in midlife schizophrenia. Based on these data, higher lifetime antipsychotic dose-years may be associated with poorer cognitive performance at age 43 years. Potential biases related to the naturalistic design may partly explain the results; nonetheless, it is possible that large antipsychotic doses harm cognition in schizophrenia in the long-term.